17th Apr 2014 15:35
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that its Incruse Ellipta treatment had been granted marketing authorisation in Canada for the treatment of chronic obstructive pulmonary disease.
Incruse Ellipta contains 62.5 micrograms of umeclidinium delivered by the Ellipta dry powder inhaler, and is used for long term, once-daily maintenance.
The Canadian approval is the first market authorisation for this product in the world.
The approval followed seven phase III clinical trials.
Shares in Glaxo closed down 0.3% at 1,559.50 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline